PreludeDx™ to Present DCISionRT® and Novel Residual Risk Subtype Study Results During Scientific Oral Session at ASBrS 2022 Annual Meeting

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Related Keywords

Australia ,United States ,Pat Whitworth ,G Bruce Mann ,Andrew Wade ,Cory Dunn ,Frank Vicini ,Instagram ,Linkedin ,Prnewswire Prelude Corporation Preludedx ,National Cancer Institute ,Nashville Breast Center ,American Society Of Breast Surgeons Asbr ,Prelude Corporation ,Facebook ,University Of California San Francisco ,Residual Risk Subtype ,American Society ,Breast Surgeons ,Scientific Session Oral Presentations ,Novel Residual Risk Subtype Identifies Patients ,Varying Risk ,Among Younger ,High Grade ,Nashville Breast ,Friday April ,Identifies Two Subsets ,Significantly Different Risk ,Local Recurrence ,Novel Biologic Subtype Was Predictive ,Elevated Recurrence Risk Despite ,Prospective Registry Study ,Clinical Utility ,Treatment Decisions ,Breast Conserving ,Royal Women ,California San Francisco ,Know Your ,Fjord Ventures ,Decision Score ,Know Your Risk ,Preludedx ,